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Abstract 
 
Background  Lung transplantation is an important option to treat patients with advanced 
Cystic Fibrosis (CF) lung disease. We report the outcomes of a large UK cohort of CF 
lung transplantation recipients. Methods: Retrospective review of case notes and 
transplantation databases. Results 176 patients with CF underwent lung transplantation at 
our centre. The majority (168) had bilateral sequential lung transplantation. Median age at 
transplantation was 26 years. Diabetes was common pre-transplantation (40%). 
Polymicrobial infection was common in individual recipients. A diverse range of 
pathogens were encountered including the Burkholderia cepacia complex (BCC). The 
bronchial anastomotic complication rate was 2%. Pulmonary function (FEV1% predicted) 
improved from pre-transplantation median 0.8 litres (21% predicted) to 2.95 litres (78% 
predicted) at one year following transplantation. We noted an acute rejection rate of 41% 
within the first month. Our survival figures were 82% survival at one year, 70% at three 
years, 62% at five years and 51% at ten years. Patients with BCC infection had poorer 
outcomes and represented the majority of those who had a septic death. We present data 
on those free from these infections. Bronchiolitis Obliterans  Syndrome (BOS) and sepsis 
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were common causes of death.  Freedom from BOS was 74% at five years and 38 % at ten 
years. Biochemical evidence of renal dysfunction was common though renal replacement 
was infrequently required (<5%). Interpretation: Lung transplantation is an important 
therapeutic option in patients with CF even in those with more complex microbiology. 
Good functional outcomes are noted although transplantation-associated morbidities 
accrue with time.  
 
Word count 250 
Introduction 
To date lung transplantation is the most intensive therapeutic intervention used in 
modern management of Cystic Fibrosis (CF). It remains the only therapeutic option that 
can restore patients with advanced cystic fibrosis lung disease towards normal respiratory 
health. Bilateral (sequential) cadaveric donor transplantation is currently the procedure of 
choice based on international data.(1)  
Long term morbidity following lung transplantation is well described both relating 
to obliterative bronchiolitis or bronchiolitis obliterans syndrome (BOS) (1), 
immunosuppressant toxicity (e.g. renal dysfunction)(2) and secondary malignancy.(1)  A 
number of single centre case series of lung transplantation for cystic fibrosis have been 
reported and demonstrate in general excellent post transplant survival results.(3-6)   
As lung transplantation does not alter extra-pulmonary manifestations of CF the 
burden of co-morbidities related to the underlying CF are important considerations in long 
term survivors.  
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We were interested to assess not only simple survival outcomes at our centre but to 
also define functional outcomes, obliterative bronchiolitis rates and other major transplant 
associated co-morbidities such as renal dysfunction and malignancy rates.  
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Aims 
We sought to assess outcomes including survival and also the prevalence of 
transplantation associated co-morbidities. 
Methods 
A retrospective analysis of case-notes, clinical charts and transplantation databases from 
the Freeman Hospital Cardiopulmonary Transplantation Unit was performed. 
Case finding and definitions 
We performed a retrospective analysis of case notes and the pulmonary transplantation 
database at our institution from 1989 (program start) to the present date. We assessed all 
recipients with Cystic Fibrosis (CF), including adult and paediatric cases, undergoing 
pulmonary transplantation and reviewed their case-notes and microbiological results. We 
have a comprehensive database of recipients with CF transplanted at our institution and 
cross referenced this with laboratory records to ensure the complete cohort was 
considered.  
Peri-transplantation management 
We used a 3-day induction protocol with anti-thymocyte globulin (titrated by flow 
cytometric analysis of peripheral blood T-lymphocytes) and intravenous 
methylprednisolone (2mg/kg). All patients had triple immunosuppression post-
transplantation comprising ciclosporin, prednisolone and azathioprin. Ciclosporin was 
commenced immediately post transplantation if renal function was satisfactory. 
Alternative agents were used in the context of an international clinical trial 
(mycophenolate) or where intolerance of ciclosporin was noted (tacrolimus). Up to five 
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days of intravenous ciclosporin was given in view of poor absorption of ciclosporin in CF.  
Prophylactic antibiotics were given to the recipient tailored to the most recent sensitivities 
derived from sputum cultures. If the isolate was pan-resistant, or recent information was 
unavailable, 2g aztreonam 8 hourly for 2-7 days was used. More recently multiple 
antibiotic synergy testing has been incorporated into our microbiological work up of such 
patients using a previously described method.(7, 8)  Aminoglycoside antibiotics were 
avoided in view of the potential synergistic toxicity with ciclosporin and loop diuretics. 
Patients were given an anti-staphylococcal agent, flucloxacillin or clindamycin, in addition 
to metronidazole. We used prophylactic nebulised amphotericin or oral itraconazole / 
voriconazole in patients who had evidence of pre-transplantation Aspergillus infection 
with positive sputum cultures for this pathogen 
Operative interventions  
These were performed as follows: Heart-Lung transplantation was performed via 
sternotomy with tracheal anastomosis and bicaval anastomosis. Bilateral (sequential) lung 
transplantation from a cadaveric donor was performed via clamshell incision with hilar 
anastomoses. In all cases the bronchial anastomosis was done with a mixture of continuous 
and interrupted mono-filament nylon. Care was taken to place the anastomosis as close as 
possible to the lung parenchyma, no further than one cartilaginous ring from the 
bifurcation of the main bronchus. All bilateral lung transplantations were done with 
cardiopulmonary bypass. In some cases, bypass was used only during implant of the 
second lung, but both lungs were reperfused simultaneously. No patients in this series 
were done without bypass. Aprotinin was used routinely. Living related lobar donor 
transplantation was also performed via clamshell incisions. 
Surveillance associated complications 
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We routinely perform surveillance transbronchial biopsies and bronchoalveolar lavage at 1 
week, 1 month, 3 months, 6 months and 1-year post transplantation and at any time of 
unexplained deterioration. Major complications of transbronchial biopsy were recorded as 
present if there was requirement for chest drain insertion, biopsy associated bleeding with 
requirement for invasive ventilation or death following a procedure. 
Airway complications 
All our recipients underwent bronchoscopic and respiratory physiology assessment and 
monitoring for anastomotic complications. Airway complications such as stenosis, 
dehiscence and need for stenting were recorded from case notes. Significant stenosis was 
deemed present if dilatation, stenting or debridement were required.(6) 
Obliterative bronchiolitis 
Pulmonary function tests were performed according to accepted guidelines. The Forced 
Expiratory Volume in 1 second (FEV1) was performed on a Sensor Medics Autobox 6200 
(Sensor Medics Corp. California, U.S.A.). The best consecutive FEV1 attained as directed 
by guidelines were used to set thresholds for BOS 1 (FEV1 66-80 % of best recorded post 
transplantation FEV1), BOS 2 (FEV1 51-65%) and BOS 3 (FEV1 <50%). The more 
recently introduced category BOS-0p was not recorded (see discussion). We  used 
“freedom from BOS” to define  patients who failed to demonstrate a fall in FEV1 to the 
threshold used for bronchiolitis obliterans syndrome BOS 1 or higher (9).  If a patient 
underwent re-transplantation the BOS rates were calculated until re-transplantation, then 
further BOS analysis was based upon standard criterion from the date of re-transplantation. 
Survival analysis and causes of death recording 
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Survival data is routinely collected as part of the national transplant surveillance program. 
Actuarial survival analysis was conducted using StatView software version 4.5. The 
causes of deaths following transplantation were recorded from the notes. If there were 
doubts to the cause of death in the absence of a post mortem examination two or more 
investigators reviewed the notes and a cause of death attributed based on supporting 
evidence in the notes. Sepsis related deaths were recorded where a pathogen was identified 
clinically and microbiologically as causal to the recipient’s terminal decline or where a 
clinical diagnosis of infection was made and other possible diagnoses were excluded. 
Renal Disease/ Dialysis requirements 
Although radio-isotope measurement of renal function using 51Chromium EDTA-GFR 
forms part of pre-transplantation assessment we do not use this technique to follow up 
patients post-transplantation. Renal function was determined by serial serum creatinine 
levels recorded pre-transplantation, at each routine clinic visit including one year after 
transplantation, at 5 years and at 10 years. The number of patients receiving renal 
replacement therapy or who had undergone secondary renal transplantation was recorded 
from case notes. 
Microbiology 
Peri-transplantation microbiology from sputum and BAL of the recipient lung on the day 
of transplantation was recorded from case-notes/microbiology database. The presence or 
absence of bacterial co-infection based on microbial culture and the commercial 
phenotyping system API-20NE (Biomerieux, L’Etoile, France) species designation was 
recorded. Pulsed field gel electrophoresis (PFGE) assessment of microbiological clonality 
was not routinely conducted. Multi-resistance and pan-resistance characteristics of 
Pseudomonas aeruginosa was recorded using previous definitions.(10) 
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Malignancy  
Solid organ or haematological malignancy rates were identified from patient case-notes 
and from cross-referencing with oncology services. Minor skin neoplasia rates due to basal 
cell carcinoma or superficial squamous cell carcinomas were not actively recorded.
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Results 
Lung transplantation commenced at this institution in 1987 with the first transplantation 
procedure for Cystic Fibrosis in 1989. The total number of lung transplantation procedures 
performed at time of writing was 575 transplants performed for all indications with 176 lung 
transplantations performed for Cystic Fibrosis patients (30% of the total lung transplant 
population). Of these 167 were adults (age greater than 17 years) and nine were paediatric cases 
(age less than 17; range 12.5-17 years).There were 91 female patients  and 85 males 
transplanted. Median age at transplantation was 26.2 years (range 12.5- 49.5 years). 
The operative interventions were 168 bilateral (sequential) lung transplantation from cadaveric 
donors (BSLTx), four heart-lung transplantation procedures, one patient received living related 
lobar donor transplantation and in two cases single lung transplantation (SLTx). One patient 
underwent BSLTX and combined liver transplantation. Additionally one CF recipient who had 
previously undergone BSLTx had “re-do” single lung transplantation performed for acute 
respiratory failure requiring intubation and mechanical ventilation This patient died after the re-
do transplant within 30 days and as a result we no longer re-transplant patients who are 
invasively ventilated. In contrast our experience with re-do transplantation, for other indications 
transplanted when stable, has a mean survival of over 2 years.  
In those recipients receiving single lung transplantation, one patient had previously had 
a pneumonectomy and the other had single lung transplantation and contra-lateral 
pneumonectomy because of thoracic wall deformity.(11) Nineteen patients had pre-
transplantation infection with Burkholderia cepacia complex and were grouped together in 
view of the association with poorer outcomes following transplantation. The outcomes in this 
group will be discussed in detail elsewhere in terms of microbiology and genomovar related 
outcomes (in submission).  
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Pre-transplantation morbidity 
Significant pre-transplantation morbidity was noted within this group; 71 patients (40%) had 
pre-transplantation diabetes mellitus the majority of whom were treated with insulin therapy. A 
further 35 patients (20% of cohort) developed diabetes following transplantation leaving 61 
(35%) at follow up with normal serum glucose levels and normal HbA1c levels with 5% of 
patients awaiting annual assessment. The majority of patients developing post-transplantation 
diabetes are established on insulin therapy (31/35). In those who developed diabetes following 
transplantation thirty-one patients were maintained on tacrolimus at time of our assessment and 
four remained on ciclosporin A. 
As previously reported pleural disease was also common.(12)  We noted 21 patients (12%) with 
a previous pneumothorax. The pre-transplantation management by referring teams included 
intercostal chest drain in 11 patients, medical pleurodesis in four patients and thoracic surgical 
pleurodesis in two patients. Survival outcomes were not worsened in those with previous 
pneumothorax (Mantel-Cox log rank testing p=0.78).(12)   An additional patient had undergone 
upper lobectomy prior to transplant listing. Previous non-invasive ventilation had been used in 
22 patients (12% of the cohort). Prior non-invasive ventilation was not associated with a poorer 
prognosis as compared to the rest of the CF cohort (Mantel-Cox log rank testing p=0.89). 
Percutaneous entero-gastrostomy (PEG) was present in 23 recipients (13%) pre-transplantation 
and overnight nasogastric feeding in 10 recipients (6%). The median body mass index was 18.6 
kg/m2 pre-transplantation (range 12-26) and this increased at 1 year to a median of 20.3 kg/m2.  
Survival and causes of death 
The survival figures for the whole cohort were 82% survival at one year, 70% at three years, 
62% at five years and 51% at ten years. Our survival figures excluding those patients with pre-
transplant Burkholderia cepacia complex infection were 84% survival at one year, 70% 
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survival at three years, 60% survival at five years, and 53% at ten years. We compared our 
Kaplan-Meier survival rates for the CF cohort to that of bilateral (sequential) lung 
transplantation for all other transplantation indications at our centre (Figure 1). There was no 
significant difference noted between survival in CF and non-CF transplantation cohorts (Log 
rank testing; Mantel- Cox, p=0.29). 
There are currently 107 CF lung transplant recipients alive (61% of cohort). Causes of death 
were not identifiable in all cases. This reflects our wide referral area and shared care with 
referring centres of post-transplant patients.  Three patients died at home or at the referring 
centre and did not have satisfactory data to confirm the recorded cause of death was correct. We 
were able to identify 35 cases where obliterative bronchiolitis or BOS was the recorded cause of 
death, accounting for 51% of all observed deaths (Table 2).  
Death due to sepsis was noted in 18 cases (of these Burkholderia cepacia complex infection 
was the cause of death in seven cases,  Clostridium difficile colitis in two cases, 
Cytomegalovirus infection in two cases, pan-resistant Pseudomonas aeruginosa in one case and 
Aspergillus infection in one case). In an additional three cases a sepsis syndrome was identified 
as the cause of death though no specific pathogen isolated. Our current sepsis death rate was 
therefore 26% of all recorded CF transplantation recipient deaths. Other causes of death were 
rare; n=1 unless otherwise stated. These included respiratory failure (n=2), primary graft 
dysfunction (n=2), acute respiratory distress syndrome (n=2), post transplant lympho-
proliferative disease (PTLD) (n=1), other malignancies; lung (n=1) and liver (=1), neurological 
complications, cardiac arrest, bronchial dehiscence and portal hypertension associated 
gastrointestinal bleeding.  
Pulmonary Function and Obliterative Bronchiolitis 
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Pulmonary function (FEV1% predicted) improved from a pre-transplantation median of 0.8 
litres (21% predicted) to 2.95 litres at 1 year following transplantation (78% predicted). The 
median FEV1 at 5 years post-transplantation was 2.75 litres and 2.2 litres at ten years post 
transplantation (p<0.01 at each time point compared to pre-transplantation values, paired t-test). 
Obliterative bronchiolitis as defined clinically by Bronchiolitis Obliterans Syndrome (BOS) 
status was BOS 0 (freedom from BOS) (9)  in 85% at 1 year, 74% at five years and 38 % at ten 
years (figure 2)  
Renal disease  
Pre-transplantation EDTA-GFR results demonstrated a median GFR of 125ml/min (range 67- 
200). Following transplantation serum creatinine worsened with a mean pre-transplant 
creatinine 73mg/dl (range 33-140mg/dl) rising to 121.5 mg/dl (range 66-235mg/dl) at one year 
(p<0.001) (Figure 3). Estimated GFR (eGFR) data are not available at time of writing reflecting 
our institutions’ recent adoption of this measurement Three patients have required 
haemodialysis (1.1% of the total CF transplant cohort- one patient remains alive). Two patients 
have undergone secondary renal transplantation (1.1% of total CF transplant cohort - one patient 
remains alive). 
Surveillance associated co-morbidities 
The majority of patients underwent our standard biopsy protocols resulting in over 800 
transbronchial biopsy procedures performed. No patient died as a consequence of a biopsy 
procedure. No cases were noted as requiring invasive mechanical ventilation or blood 
transfusion following a transbronchial biopsy. Reflecting the recently instituted prospective 
electronic data basing of biopsy results we identified 438 biopsies taken within the first year. 
Acute vascular rejection (ISHLT grade A2 or greater) was noted in 77 of 187 biopsies taken 
within the first month (0-30 days). Thus biopsy data gave an observed first month acute 
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vascular rejection rate of 41%. We identified 32/251 cases of acute rejection from day 30-366 
post transplantation as part of our routine surveillance program. This rejection rate equates to 
12% of biopsies undertaken between 1 month and 1 year post transplantation.  
Malignancy 
One patient suffered donor acquired small cell lung carcinoma as previously reported.(13) Post 
transplant lympho-proliferative disease (PTLD) was noted in five patients (2.8% of cohort). 
Microbiology 
Peri-transplantation microbiological cultures, including those prior to transplantation 
and within the first week following transplantation were achieved in all patients. A large range 
of pathogens were seen in the cohort and polymicrobial infections in individual recipients were 
common (Figure 4). Infection with more than one Pseudomonas strain was assumed in the 
presence of mucoid and non-mucoid phenotypes and / or widely differing antibiotic 
sensitivities. Pulsed field gel electrophoresis studies (PFGE) that assess different bacterial 
lineages were not routinely conducted so our assumption may be incorrect and such bacteria 
could include some clonal strains with marked morphotypic/ phenotypic variation. Noting this 
caveat, we found 54% of patients appeared to have two or more distinct Pseudomonas strains. 
A further 14% of patients had pan-resistant Pseudomonas aeruginosa infections and similarly 
14% of patients had multi-resistant Pseudomonas aeruginosa infections. Burkholderia cepacia 
complex infections were noted in 15%, Aspergillus infection in 12%, Stenotrophomonas spp. 
infection in 9%, Alcaligenes  spp. infections in 6%, Scedosporium spp. infections in 2% and 
methicillin resistant S. aureus infection (MRSA) in 2%. Atypical mycobacteria were not 
isolated in our cohort at the time of transplantation though infection with such organisms does 
not reflect a specific exclusion criteria for transplantation at this centre.  
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Airway complications 
In 176 recipients with 346 bronchial anastomoses we noted four recipients with major 
anastomotic complications (overall major bronchial anastomotic complication rate 2%). One 
recipient suffered bronchial dehiscence. Three recipients had anastomotic strictures that 
required dilatation and stenting. 
 16 
Discussion 
Lung transplantation for Cystic Fibrosis accounts for approximately one-third of 
all sequential single lung transplants performed at this centre, a distribution similar to that 
reported by the International Society for Heart Lung Transplantation (ISHLT) registry.(1) 
Our series of cystic fibrosis lung transplants is one of the largest reported to date and our 
survival rates are similar to the best of the previously reported series.(10, 14-16) The 
survival rates for CF recipients reported by Egan et al where similar to our centre, most 
procedures were bilateral sequential single lung transplantation, were 81% at 1 year, 59% 
at 5 years, and 38% at 10 years.(17) Our approach has been predominantly with bilateral 
sequential single lung transplantation and this compares favourably with that of heart-lung 
transplantation for cystic fibrosis.(18) 
The predominant surgical technique used was bilateral sequential single lung 
transplantation with cardiopulmonary bypass. Routine use of bypass facilitated a standard 
technique across a relatively large surgical and anaesthetic team. Both main bronchi were 
stapled after recipient pneumonectomy, facilitated by  the single lumen endotracheal tube 
which allowed irrigation and removal of contaminated secretions from the (retained) distal 
airway. We believe this technique reduces intra-operative contamination. Finally, 
reperfusion of both lungs simultaneously allows close control of pressure and avoids 
circulatory overload of one lung.   
Bronchial anastomotic complications were uncommon with an overall major 
bronchial anastomotic complication rate of 2% in comparison to prior reports in CF 
recipients of up to 7% and 14%.(24, 25)  More recently rates of anastomotic 
complications in a cohort including CF and other lung transplantation indications were  
15%.(26) The reasons for our low anastomotic complication rates remain unclear. We did 
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not, however, routinely perform bronchial artery revascularisation (possible protective 
benefits)(27, 28) nor did we routinely perform telescoping of the bronchial anastomosis 
(possible promoter of anastomotic complications).(26) We do not however have data on 
other factors recently implicated in the genesis of anastomotic complications such as 
recipient length and donor ventilation times.(26) Despite our low rates of anastomotic 
complications one episode was felt to have directly contributed to the recipient’s 
death.  
We noted a high rate of pathogens with potential to complicate the early post-
operative period including pan-resistant Pseudomonas aeruginosa, Burkholderia cepacia 
complex and Aspergillus species. We compared our CF cohort to that of all other bilateral 
sequential lung transplants performed at our centre (including non-CF bronchiectasis, 
sarcoidosis, emphysema) and found no significant differences in survival rates (log rank 
testing p=0.29) Confounding variables between CF recipients and non-CF recipients may 
however include differing recipient ages and co-morbidities in these two cohorts.    
Most of the early deaths (deaths within the first 30 days) following lung 
transplantation for CF were felt due to sepsis. We noted 26% of our CF recipient deaths 
were due to sepsis, which is also comparable to or less than that reported from other 
centres.(6, 14) There were significantly higher mortality rates in those who had pre-
operative B. cepacia complex (BCC) infection where 7 of 19 patients died due to sepsis 
(36%). The observed higher risk of death due to sepsis in those with pre-transplantation 
BCC infection confirms that of prior reports demonstrating excessive mortality in BCC 
infected patients.(14, 19)  Our full experience of transplantation with Burkholderia 
cepacia complex infection and genomovar specific outcomes will be discussed elsewhere 
(in press).  
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No other organisms were significantly associated with poor transplantation 
outcomes. In particular infection with multi- or pan-resistant Pseudomonas aeruginosa 
had no survival disadvantage confirming prior findings (10, 20, 21) but in contrast to a 
more recent publication.(16) None of our recipients had pre-transplantation infection with 
non-Tuberculous Mycobacteria (NTM). This does not reflect a specific policy of 
declining to transplant individuals with such infections although we do not transplant  
those infected with M. abscessus due to concerns over post transplantation morbidity. (22) 
We did not prospectively assess the clonal nature of bacterial strains with pulsed 
field gel electrophoresis and assumed that strains with markedly different antibiograms 
and morphotypes were unrelated clonally. This phenotypic approach may over-estimate 
the number of distinct species of organisms or strains isolated noted in Figure 4. 
Pre-transplantation co-morbidity was common with significant rates of CF related 
diabetes, Cf related liver disease, prior pneumothorax or chest surgery and weight loss. 
We do not view CF related liver disease as a contraindication per se though we regularly 
seek expert assessment hepatobiliary and liver transplant colleagues. Despite this 
multidisciplinary approach one patient died of hepatobiliary complications related to 
variceal bleeding following transplantation.  Low body mass index was noted in selected 
patients with the lowest recorded pre-transplantation BMI of 12kg/m2. In general we 
prefer to avoid transplanting patients with a BMI less than 16kg/m2 but may elect to do so 
if the potential recipient has no other relative contra-indications and has made maximal 
efforts with assisted nutrition. Interestingly there was no clear association between poor 
post- transplant survival and prior pneumothorax or prior non-invasive ventilation. 
We noted a good functional outcome following transplantation with an increase in 
FEV1 at one year following transplantation to almost 3 litres (78% predicted).   Similar to 
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prior reports we used “freedom from BOS” as defined by patients who failed to 
demonstrate a fall in FEV1 to the criterion used for bronchiolitis obliterans syndrome 
BOS 1 or higher.(15) The majority of patients were free from BOS 1 or higher at one year 
(~85%) and 73.6% at 5 years. In those recipients surviving ten years 37.5% of patients 
had freedom from BOS 1. Similar “freedom from bronchiolitis obliterans syndrome” rates 
in CF recipients have been reported at the Rome transplant program as 95% at one year, 
82.5% at two years, 70% at three years, and 65% at five years.(9) Earlier reports have 
demonstrated freedom from bronchiolitis obliterans syndrome as 84% at 1 year and 
51% at 3 years.(15) One possible criticism using “Freedom from BOS” and not the 
newly categorised BOS 0-p is that our study cannot report those at risk of BOS. We were 
unable to report BOS 0-p due to the large numbers of patients being transplanted prior to 
the introduction of the new BOS 0-p category where FEF25-75 data was unavailable. 
Transplantation in our CF cohort was associated with significant post-
transplantation co-morbidities, in particular, renal dysfunction.(2) In a smaller series 
previously reported three patients (11% of total CF recipients) required dialysis following 
lung transplantation. In the series of 55 Italian CF recipients reported by Quattrucci et al 
(9) the authors noted that the most common medical complication after transplantation, 
observed in 27 patients, was chronic renal failure. Our rates of renal dysfunction are 
therefore lower than those previously reported. This is noteworthy as we now have an 
aggressive policy in non-rejecters (those with biopsies all of grade A1 or less) to reduce 
target ciclosporin or tacrolimus levels by the end of the first year. Such a strategy may 
however be ineffective as the majority of nephron loss has been postulated to occur in the 
first year following transplantation.(23) Whilst aggressive aminoglycoside antibiotic 
therapy may stabilise patients with CF on a transplant waiting list we did not specifically 
assess if those patients with lower transplant assessment EDTA-GFR recordings had 
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received more courses of these potentially nephrotoxic antibiotics.  Irrespective of this, the 
level of post-transplantation renal dysfunction in this cohort has remained low.  
Other important major post transplantation complications encountered in our 
cohort have included four recipients who developed fulminant pseudo-membranous colitis 
where the mortality rate was 50% despite urgent colectomy.(29) One patient has 
required a post transplantation left pneumonectomy related to pulmonary vascular 
anastomosis compromise associated with mediastinal lymphadenopathy).  
Post-transplantation bronchoscopy and surveillance-associated morbidity was 
extremely low, had a high detection rate of asymptomatic acute vascular rejection similar 
to that recently reported.(30) Many of these rejection episodes were asymptomatic and not 
associated with an obvious fall in lung function. The surveillance protocols used at our 
centre have also contributed to our understanding of post transplantation graft dysfunction 
offering hope in extending the longevity of both the graft and recipient.(31-33) 
The retrospective nature of our study, has by definition, inherent weaknesses. 
Many of the deaths were not confirmed by autopsy findings leading to potential  incorrect 
categorisation of the cause of death for example BOS may be associated with secondary 
bacterial infection and this makes the cause of death difficult to differentiate.  Autopsy 
should be considered where possible if the cause of decline is not clear. Also of note is the 
lack of prospective data on metabolic bone disease, a common co-morbid condition in CF.  
Although we are unaware of any known osteoporotic fractures, a systematic bone density 
assessment programme following transplantation was not adopted until recently. Other 
important areas to be considered for future studies would include employment status, 
assessments of psychiatric morbidity and quality of life measurements.  
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Bilateral sequential lung transplantation is a well-established treatment for patients 
with end-stage CF associated lung disease. The peri-operative mortality is low and 
recipients with CF have a significant early survival and functional benefit after lung 
transplantation. Long-term results are good although both transplantation associated co-
morbidities and increasing rates of graft dysfunction occur with time. 
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Figure 1 Actuarial Survival of Cystic Fibrosis patients at the Freeman 
Hospital Lung Transplant Programme as compared to all other 
sequential single lung transplants performed. 
 
 
 
Key Solid line represents actuarial survival for the Cystic Fibrosis 
recipients receiving bilateral sequential single lung transplants (BSLTx), 
Dashed line represents all other BSLTX  performed at our centre 
(n=100). No significant difference in survival was found between the 
cohorts (Log rank testing; Mantel-Cox, p=0.29). 
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Table 1 Comparison of Published Actuarial Survival Figures for Lung 
Transplantation in Cystic Fibrosis  recipients  from selected case series 
 
Key; Newcastle survival data at  one year (1 yr). NR represents not recorded,  n=  represents 
recipient numbers, Newcastle (excluding BCC) represents our transplantation results for 
Cystic Fibrosis excluding those with pre transplantation Burkholderia cepacia complex 
infection (includes BSLTx and other operative interventions). The actual number of patients 
surviving at each time point is noted in italics. Data reported elsewhere includes Egan et al 
(see reference (17), Burton et  al  (5), Quatrucci et al (9) . Hadjiliadis et al represents 
survival outcomes in CF recipients with sensitive organisms (sens) and pan-resistant 
organisms (PanR)  (16). 
 
 
 Newcastle Newcastle 
(excl. 
BCC) 
Egan  
et al  
Burton 
et al 
Quatrucci 
et al  
Hadjiliadis 
et al (sens) 
Hadjiliadis 
et al (PanR) 
1 yr 82 85 (134) 81 89 79 96 88 
3yr 70 72 (97) NR 80 70 91 63 
5yr 62 62 (63) 59 80 58 85 58 
8yr 56 56 (33) NR 70 NR NR NR 
10yr 51 53 (19) 38 NR NR NR NR 
n= 176 157 123 36 55 58 45 
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Table 2 Causes of Death in Cystic Fibrosis recipients transplanted at the Freeman 
Hospital Transplant Programme. 
 
Key; Causes of death in recipients were recorded from case notes. Data 
is expressed as percentage of all deaths observed in this cohort. Thirty 
five cases of obliterative bronchiolitis were identified and this accounted 
for 51% of all deaths in the cohort. The percentages have been rounded 
up or down to the 1st decimal place. 
Cause of Death Number of patients 
Obliterative Bronchiolitis 35 (51%) 
Infection  18 (26%) 
B. cepacia complex 
Cytomegalovirus 
C. difficile 
Aspergillus spp. 
Ps. aeruginosa 
Unknown 
7 (10%) 
2 (3%) 
2 (3%) 
1 (1.5%) 
1 (1.5%) 
5 (7%) 
Respiratory failure 2 (3%) 
Malignancy 2 (3%) 
Acute Resp Distress 
Syndrome  
2 (3%) 
Graft dysfunction 2 (3% 
Gastrointestinal bleed 1 (1.5%) 
PTLD 1 (1.5%) 
Cardiac arrest 1 (1.5%) 
Bronchial dehiscence 1 (1.5%) 
Neurological complications 1 (1.5%) 
Unknown 3 (4.5%) 
Total Number of Deaths 69 (100%) 
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Figure 2 Rates of Bronchiolitis Obliterans Syndrome (BOS) in Cystic Fibrosis 
recipients. 
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Key to Figure 2 
Freedom from Bronchiolitis Obliterans Syndrome (BOS) at 1 year (n=134), 5 years (n=63) and 
10 years (n=19) following transplantation. Key striped bars -CF recipients with BOS grade 1 or 
higher, Solid bars -CF recipients who had “freedom from BOS”, Open Bars - patients where 
data was not available. 
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Figure 3 Change in serum creatinine (mg/dl) following transplantation.  
 
Key Solid line- median creatinine level observed. Dashed lines represent the 
25th and 75th Centile creatinine levels. 
 
 
0
50
100
150
200
250
0 2 4 6 8 10
Years
cr
ea
tin
in
e 
m
g/
dl
 31 
 
Figure 4 Microbial infection rates in the transplanted cohort 
 
Key 
 
Percentage of the cohort infected with each pathogen is noted. Co-infection 
was common with many patients having poly-microbial infections. The first 
histogram represents patients infected with more than one Pseudomonas 
species or strain. Multi-resistance (Multi-R) and pan-resistant (pan-R) was as 
defined previously(10). MRSA- represents methicillin resistant S. aureus. 
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